Literature DB >> 22920927

Application of the Seattle heart failure model in patients >80 years of age enrolled in a tertiary care heart failure clinic.

Hanane Benbarkat1, Karima Addetia, Mark J Eisenberg, Richard Sheppard, Kristian B Filion, Caroline Michel.   

Abstract

The Seattle Heart Failure Model (SHFM) is 1 of the most widely used tools to predict survival in patients with heart failure. However, it does not accommodate very elderly patients. We decided to assess the applicability of the SHFM in patients >80 years old enrolled in a tertiary care heart failure clinic. We evaluated the difference between observed survival and mean life expectancy as predicted by the SHFM on 261 patients >80 years old enrolled in a heart failure clinic at the Jewish General Hospital, Montreal, Quebec, Canada from January 2002 through March 2010. Average age of the patient population was 85 ± 4 years (range 80 to 105). Sixty-two percent of the population consisted of men, 63% had ischemic cardiomyopathy (ICM), and average ejection fraction was 36 ± 18%. Median observed survival was 1.91 years (interquartile range 0.68 to 5.53) for the total population (n = 261). The SHFM (predicted median survival 6.7 years, interquartile range 3.8 to 11.2) overestimated life expectancy by an average of 4.79 years. For patients with ICM (n = 164) versus non-ICM (n = 97), the score overestimated survival by 4.29 versus 5.69 years, respectively. In conclusion, the SHFM overestimates life expectancy in elderly patients followed in a tertiary care heart failure clinic. Further studies are needed to more accurately estimate prognosis in this patient population.
Copyright © 2012 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2012        PMID: 22920927     DOI: 10.1016/j.amjcard.2012.07.034

Source DB:  PubMed          Journal:  Am J Cardiol        ISSN: 0002-9149            Impact factor:   2.778


  6 in total

1.  Physical and psychological symptom profiling and event-free survival in adults with moderate to advanced heart failure.

Authors:  Christopher S Lee; Jill M Gelow; Quin E Denfeld; James O Mudd; Donna Burgess; Jennifer K Green; Shirin O Hiatt; Corrine Y Jurgens
Journal:  J Cardiovasc Nurs       Date:  2014-07       Impact factor: 2.083

2.  Patient selection for advanced heart failure therapy referral.

Authors:  Alexander C Fanaroff; Adam D DeVore; Robert J Mentz; Mani A Daneshmand; Chetan B Patel
Journal:  Crit Pathw Cardiol       Date:  2014-03

3.  Is cardiopulmonary exercise testing essential to indicate ventricular assist device implantation in patients with INTERMACS profile 4-7?

Authors:  Teruhiko Imamura; Koichiro Kinugawa; Daisuke Nitta; Osamu Kinoshita; Kan Nawata; Minoru Ono
Journal:  J Artif Organs       Date:  2016-03-18       Impact factor: 1.731

4.  Heart failure in elderly: progress in clinical evaluation and therapeutic approach.

Authors:  Massimo Iacoviello; Valeria Antoncecchi
Journal:  J Geriatr Cardiol       Date:  2013-06       Impact factor: 3.327

5.  Plasma amino acid profiling improves predictive accuracy of adverse events in patients with heart failure.

Authors:  Hidemichi Kouzu; Satoshi Katano; Toshiyuki Yano; Katsuhiko Ohori; Ryohei Nagaoka; Takuya Inoue; Yuhei Takamura; Tomoyuki Ishigo; Ayako Watanabe; Masayuki Koyama; Nobutaka Nagano; Takefumi Fujito; Ryo Nishikawa; Wataru Ohwada; Tetsuji Miura
Journal:  ESC Heart Fail       Date:  2021-09-06

6.  Association of heart failure and its comorbidities with loss of life expectancy.

Authors:  Michael Drozd; Samuel D Relton; Andrew M N Walker; Thomas A Slater; John Gierula; Maria F Paton; Judith Lowry; Sam Straw; Aaron Koshy; Melanie McGinlay; Alexander D Simms; V Kate Gatenby; Robert J Sapsford; Klaus K Witte; Mark T Kearney; Richard M Cubbon
Journal:  Heart       Date:  2020-11-05       Impact factor: 5.994

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.